Business
SERA PROGNOSTICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS
Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2024.
About this update from Sera Prognostics, Inc.
[{"type":"text","content":"SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2024.","length":335,"tagName":"p"},{"type":"image","alt":"Sera Prognostics (PRNewsfoto/Sera Prognostics, Inc.)","displaySize":"","headline":null,"caption":"Sera Prognostics (PRNewsfoto/Sera Prognostics, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":90,"url":"https://media.zenfs.com/en/prnewswire.com/d1d944ffbad708c79d61709e5cb91780"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/g3shuPcAHtDCV.D5czkFkw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE1OTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/d1d944ffbad708c79d61709e5cb91780","width":400,"height":90}},"href":"https://mma.prnewswire.com/media/1670603/Sera_Prognostics_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Recent Highlights:","length":18,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"On January 6, 2025, the Society for Maternal Fetal Medicine ("SMFM") published an abstract reporting topline results for Sera's Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PRIME") study.","length":265,"tagName":"p"}]},{"val":[{"type":"text","content":"Results of the PRIME study were also accepted as a late-breaking abstract for oral podium presentation at the SMFM 2025 Pregnancy Meeting™ on January 31, 2025, widely considered the world's leading conference on the subject of pregnancy. During this event, Dr. Brian Iriye – maternal-fetal medicine expert at the High Risk Pregnancy Center in Las Vegas, Nevada, and principal investigator for the PRIME study – presented the results of the full PRIME study. Among other notable results, the study showed that both primary outcomes met success criteria, showing a 25% reduction in neonatal morbidity and mortality index (NMI) and an 18% reduction in neonatal length of hospital stay among the pre-specified modified intent-to-treat population. Further, the study showed a 20% reduction in NMI and 22% reduction in NICU admissions among a broader inten...